Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL3921377

O=C(O)C(F)(F)F.O=c1cc(OCc2ccccn2)c2cc(Cl)ccc2o1

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KMO O15229 2/20 0.44
▸ SLC6A4 P31645 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ ALDH1A1 P00352 2/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ MRGPRX4 Q96LA9 1/20 0.41
▸ ALOX5 P09917 1/20 0.40
▸ ALOX5AP P20292 1/20 0.40
▸ KCNA3 P22001 1/20 0.40
▸ SLC16A3 O15427 1/20 0.39
▸ NPC1 O15118 2/20 0.39
▸ RAB9A P51151 2/20 0.39
▸ MAPT P10636 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ SYK P43405 2/20 0.39
▸ AURKB Q96GD4 1/20 0.39
▸ INCENP Q9NQS7 1/20 0.39
▸ TSHR P16473 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3912910 0.91 SLC6A4 (0.49) KMOSLC6A4ALDH1A1L3MBTL1KCNA3
Trifluoroacetic Acid SCHEMBL3909784 0.84 AR (0.47) SLC6A4KMT2AALDH1A1
Trifluoroacetic Acid SCHEMBL3923215 0.82 LRRK2 (0.44) SLC6A4KMT2AMAPTSMN1; SMN2
Trifluoroacetic Acid SCHEMBL3923252 0.79 KCNA3 (0.46) ALDH1A1KCNA3
Trifluoroacetic Acid SCHEMBL3918872 0.79 MRGPRX4 (0.44) MRGPRX4
Trifluoroacetic Acid SCHEMBL5728404 0.79 HTR2C (0.44) ALDH1A1KCNA3SMN1; SMN2TSHR
Trifluoroacetic Acid SCHEMBL3925125 0.78 KCNA3 (0.45) ALDH1A1KCNA3
Trifluoroacetic Acid SCHEMBL3913356 0.78 HTR2C (0.45) ALDH1A1KCNA3TSHR
SCHEMBL13840577 0.77 PKM (0.54) ALDH1A1L3MBTL1NPC1RAB9ATSHR
Trifluoroacetic Acid SCHEMBL3910499 0.76 ALDH1A1 (0.51) KMT2AALDH1A1L3MBTL1KCNA3SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1667988-B1 COUMARINS AS INOS INHIBITORS AVENTIS PHARMA INC (US) 2013-04-10 — — EP disclosed
US-7538233-B2 Coumarins as iNOS inhibitors AVENTIS PHARMACEUTICALS INC. (US) 2009-05-26 — — US disclosed
EP-1667988-A1 COUMARINS AS INOS INHIBITORS Aventis Pharmaceuticals Inc. (US) 2006-06-14 — — EP disclosed
WO-2005026143-A1 COUMARINS AS INOS INHIBITORS AVENTIS PHARMACEUTICALS INC. (US) 2005-03-24 — — WO disclosed
US-20050054681-A1 Coumarins as iNOS inhibitors AVENTIS PHARMACEUTICALS INC. (US) 2005-03-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054681-A1 Coumarins as iNOS inhibitors NOS2, NOS1, NOS3 KMO 426/4885SLC6A4 3218/4885KMT2A 4703/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback